Chinook Therapeutics Inc (KDNY) · page 23 of 36
Includes a table detailing orphan drug designation and marketing approval for Filspari (sparsentan).
Research note · preempt_rebuttal · preempt_rebuttal · balanced density
Slide locked Sign in to view
Slide schematic 5/5
paragraph 3/3 source-note 1/1 table 1/1
Components 5
paragraph paragraph paragraph source-note data
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1